Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CDI-988

Small molecule · developed by Cocrystal Pharma

Phase 1/2 Most advanced trial

COCP Developer

1 Registered trials

What is CDI-988?

CDI-988 is an antiviral agent studied for the treatment of norovirus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Infectious disease
Developer: Cocrystal Pharma, Inc. (COCP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07198139	Phase 1/2	Norovirus	Recruiting	COCP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Norovirus

More from Cocrystal Pharma

CC-42344 Phase 2 CDI-31244 Phase 2

Sources

ClinicalTrials.gov NCT07198139

Updated Oct 11, 2026. Something wrong or missing? Report it on the COCP page.

Follow COCP, the company behind CDI-988

See COCP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

COCP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z